MedTrace Logo

Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease

NCT02112812 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2014-04-14

No results posted yet for this study

Summary

A higher prevalence of Helicobacter pylori infection rate has been demonstrated among PD patients compared to controls. As H. pylori infection is known to interfere with levodopa absorption, we embarked on this is a study to understand the effects of Helicobacter pylori infection eradication among a selected Malaysian population with Parkinsons disease, in relation to levodopa effectiveness and motor improvements.

The study hypotheses are:

1. H. pylori eradication improves L-dopa 'onset' time and prolongs the L-dopa 'on-time' duration.
2. PD patients with H. pylori infection show clinical improvement in motor disability and quality of life after eradication therapy of H. pylori, assessed using UPDRS-III / PDQ39 questionnaires.

Conditions

  • Response to Levodopa
  • Motor Outcomes
  • Quality of Life Outcomes

Interventions

DRUG

Eradication therapy for H.pylori infection

Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.

DRUG

Eradication of Helcobacter Pylori

Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd

DRUG

Eradication therapy for Helicobacter pylori

Sponsors & Collaborators

  • National University of Malaysia

    lead OTHER

Principal Investigators

  • Norlinah Mohamed Ibrahim, MBBCH, MRCP · Department of Medicine, Faculty of Medicine, National University of Malaysia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • Malaysia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02112812 on ClinicalTrials.gov